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1. Introduction
Non-viral gene therapy vectors are highly desirable tools for the introduction of DNA into
cells; they have better safety profiles than viral methods of delivery and are more amenable to
repeated administration. Non-viral vectors include naked DNA, cationic lipid-DNA com‐
plexes (lipoplex), polymer-DNA complexes (polyplex) or combinations of lipids and polymers.
Successful gene delivery depends upon the ability of the vector of choice to target a specific
cell type, enter the cell and obtain sufficient levels of gene expression. This is not a simple task
since there are several barriers encountered by both viral and non-viral vectors that make this
process difficult. First, the vector must have a method by which to target a specific cell type,
while also avoiding extracellular insults including nucleases and the immune system. Next,
once the vector has reached its particular target, it must traverse the plasma membrane
and/or escape the endosome, and pass through the dense cytoskeletal network en route to the
nucleus. The nuclear envelope presents a final barrier, since DNA must enter the nucleus in
order to be transcribed. While viruses have evolved mechanisms to enter target cells, deliver
their genetic material and continue to propagate, non-viral systems lack these innate mecha‐
nisms. Consequently, there has been much work aimed at characterizing and overcoming these
barriers in order to improve the efficacy of these vectors.
2. Extracellular barriers
Regardless of the method by which a non-viral vector is administered in vivo (e.g., by inhalation,
intramuscular injection, gavage, intravascular injection, etc), it will unavoidably come into con‐
tact with the extracellular environment. Within the extracellular milieu, multiple factors exist
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which can result in rapid clearance and/or degradation of the vector before it ever reaches its
targeted organ. Intravenously delivered naked DNA has been shown to have a very short half-
life within serum, on the range of 1.2 to 21 minutes depending upon the topoform of the DNA
[1]. This is believed to be the result of both endo and exonuclease activity in the plasma. Similar
degradation has been observed in plasmid DNA delivered intramuscularly [2]. Strategies to
protect DNA from nuclease activity include the use of cationic lipids, such as DOTAP:DOPE, to
encapsulate the plasmid and shield it from the enzymatic environment outside the cell [1]. In
addition, the use of PEGylated lipids and polymers has been demonstrated to enhance the sta‐
bility of complexes in serum, greatly lengthening the vectors' half-life [3].
DNA that does evade nucleases, however, also comes into contact with proteins and cells
within the extracellular environment. Serum contains a variety of proteins which have the
ability to bind to non-viral vectors and, as a result, inhibit the biological activity of the vector
or sequester it for degradation and/or removal. For example, negatively charged serum
proteins form connections between cationic liposomes, which results in the aggregration of
the delivery vehicles. When this happens, the vectors are quickly removed from circulation by
the reticuloendothelial system. Some of the key blood proteins that have been identified to
associate with non-viral vectors include albumin, complement, immunoglobulins, fibronectin,
apolipoproteins, C-reactive protein, and b2-glycoprotein I [4]. PEGylation of both lipolexes
and polyplexes as well as the use of cholesterol as a helper lipid have shown promise in the
prevention of this type of aggregation [3].
It is important to note that DNA delivery vehicles also come into contact with blood cells. These
cells, which include erythrocytes, leukocytes, macrophages, and platelets, have a negative
surface charge, thereby allowing for electrostatic interactions to occur between cells and
cationic vectors. In particular, the interaction of lipoplexes with erythrocytes has been shown
to be a significant factor in in vivo gene delivery, as binding occurs within minutes of in vivo
intravenous gene transfer [5]. The vector is then able to directly associate (in the case of
DOTMA/cholesterol complexes) and/or fuse (in the case of DOTMA/DOPE complexes) with
erythrocytes, thereby decreasing transfection efficiency and encouraging removal of the
delivery vehicle by way of the liver and spleen [5]. (Since erythrocytes have no nuclei, entry
of vectors into these cells represents a dead end.) In the lung, the alveolar macrophage is
regarded as a major barrier to both viral and non-viral delivery since this professional
phagocytic cell "eats" up delivery agents before they can transfect any other cell type [6].
Another extracellular barrier to consider is activation of the immune system. While immune
activation has been most associated with viral gene delivery, some non-viral methods have
been shown to induce an immune response. For example, intravenously injected cationic
lipoplexes can induce an inflammatory response involving the release of TNFα and IFNγ into
the serum [7]. This is believed to be a result of unmethylated CpG motifs on the plasmid DNA
and the subsequent recognition by Toll-like receptors [8, 9]. Thus, the removal of these CpG
motifs is important for successful gene delivery [10]. The cationic polymer, PEI, has also been
shown to activate the immune system through complement and activation of both a Th1 and
Th2 response [11] Finally, as previously discussed, PEGylation of non-viral vectors is a
common technique used for avoiding some extracellular barriers, however the production of
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anti-PEG IgM has the potential to interfere with repeated administration of the vector [12-17].
Thus, much care and consideration must be put into the selection of the proper non-viral vector
for specific disease therapeutics.
3. The plasma membrane
Once the delivery vehicle has reached a cell, it then encounters a second significant barrier: the
plasma membrane. Successful transfection relies on the ability of the vector to enter the cell of
interest. In the absence of a delivery vehicle, naked DNA does not efficiently associate with the
plasma membrane due to the negative charge density on both the DNA and the cell surface. De‐
livery vehicles help circumvent this problem through the use of polycations to neutralize the
negative charge of the DNA, thereby increasing association with the plasma membrane. This
non-specific electrostatic association is mediated largely by heparin sulfate proteoglycans on
the cell surface that trigger endocytosis of the delivery vehicle and entry into the cell.
While most chemical transfection methods require endocytosis for transport across the plasma
membrane into the cytoplasm, more recently, several short peptides have been reported to
facilitate cell entry in an endocytosis-independent manner [18-20]. These have been termed
cell-penetrating peptides (CPPs) and include peptides from proteins such as Tat, antennape‐
dia, and penetratin as well as polyarginine peptides. Depending upon the CPP used, different
internalization mechanisms are used to access the cytoplasm including direct transduction
through the lipid bilayer as well as energy-dependent macropinocytosis [21]. Regardless of
the mechanism for cell entry, these peptides may prove very useful in delivery of small DNAs
and synthetic RNAs.
Physical methods of gene delivery, such as the gene gun, electroporation (electric fields),
sonoporation (ultrasound) and hydrodynamic (high pressure) delivery can also facilitate
delivery of DNA across the plasma membrane. The gene gun utilizes metal particles coated
with plasmid DNA that are accelerated and bombard a tissue of interest [22]. This technique,
however is limited by the superficial penetration of the DNA into the tissue and is therefore
most successful for percutaneous delivery of DNA. Electroporation is a more versatile
technique that has been used on a variety of tissues with success. During this process, a series
of electrical pulses are delivered that result in destabilization of the cell membrane. Transient
pores are then created which allow the passage of plasmid DNA into the cell. Blood vessels,
skin, muscle, heart, liver, and lung have all been successfully transfected with electroporation
[23-27]. Sonoporation has seen most success in soft tissues and it’s use deep within the body
is a major potential strength. This technique uses ultrasound to enhance cell permeability
through acoustic cavitation and subsequent gene transfer through passive diffusion of DNA
across pores in the cell membranes. A number of in vivo studies have demonstrated successful
gene transfer in skeletal muscle, cardiac muscle, kidney, carotid artery, pancreas and liver of
mice and rats [28-37]. Finally, hydrodynamic gene delivery is a highly efficient method for
gene transfer to highly perfused organs such as the liver or muscle in peripheral limbs. A large
volume of DNA injected into the tail vein of a mouse has been shown to result in transient
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membrane changes in hepatocytes, resulting in direct transfer of DNA into the cytoplasm [38,
39]. Like electroporation and sonoporation, pores within the plasma membrane are thought
to be formed allowing entry of plasmids, in this case by the rapid change in hydrostatic
pressure [40]. Modifications of this technique using balloon catheters in larger animals has
suggested potential for ultimate success in humans as well [41-43].
While all of these approaches facilitate endocytosis or direct entry into the cytoplasm of any
cell type, one of the goals of gene therapy is often cell-specific targeting. Thus, the development
of delivery vehicles that only interact with specific cell types is highly desirable. In most cases,
cell-specificity is acheived by specific interactions between ligands on the vector and receptors
on the cell surface. For example, as many tumor cells overexpress receptors for nutrients, such
as folate and transferrin, this phentoype has been exploited for the development of DNA and
drug delivery vehicles carrying either folic acid or transferrin as ligands. Recently, a transfer‐
rin-PEG-PE conjugated cationic lipid carrier and a PEG-transferrin-PEI nanocomplex were
developed, which exhibited increased transfection efficiency in vitro as well as in vivo [44,
45]. Similar results have been obtained using folate linked nanoparticles as well [46]. Delivery
of DNA to specific cell types has also been achieved through the use of glycosylated carriers,
specifically cationic liposomes [47]. Mannosylated and galactose conjugated liposomes have
demonstrated efficacy as delivery agents for macrophages and hepatocytes [48, 49].
4. Vector release and cytoplasmic trafficking
Gene  delivery  vectors  that  utilize  endocytosis  to  access  the  cytoplasm  are  then  moved
through the endocytic compartment. Thus, another major barrier to successful gene deliv‐
ery is the release of the DNA from the endosome before it is degraded at the lysosomal
level.  There  are  several  mechanisms  employed  to  increase  the  likelihood  of  endosomal
escape  including  membrane  fusion,  the  proton-sponge  effect  and incorporation  of  fuso‐
genic and pore-forming peptides.
Lipoplexes are able to escape the endosome through fusion of the liposome with the en‐
dosomal membrane. In particular, inclusion of dioleoylphosphatidylethanolamine (DOPE)
has been shown to enhance endosomal escape due to its ability to transition from bilayer
to inverted hexagonal structures [50, 51]. The instability of this type of structure increas‐
es fusion with endosomes and subsequently releases the DNA [52].  This is not common
across all lipids as a similar phospholipid, dioleoylphosphatidylcholine (DOPC), does not
exhibit  similar  activity  [53,  54].  Therefore,  complex structure  plays  an important  role  in
enhancement of endosomal escape.
In contrast to lipoplexes, cationic polymers such as PEI achieve endosomal escape through a
‘proton sponge’ mechanism. PEI possesses a very high buffering capacity due to the presence of
amino nitrogen at every third atom, which can be protonated within the acidifying endosomes.
Consequently, an accumulation of protons causes an influx of chloride ions thereby resulting in
osmotic swelling and lysis of the endosome. Therefore, use of cationic polymers with this type
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of buffering capacity increases the amount of time before passage of DNA to lysosomes, which
therefore increases the likelihood of the DNA getting transferred to the cytoplasm.
Finally, many fusogenic and pore-forming peptides have been discovered and incorporat‐
ed into gene delivery vehicles. The influenza-derived peptides GALA and KALA under‐
go  pH-dependent  conformational  changes  that  result  in  disruption  of  endosomal
membranes [55-58]. Several bacteria derived and animal derived peptides with membrane
disruptive properties have also been developed and appear to increase endosomal escape
and transfection efficiency [59].
Once DNA has successfully been released into the cytoplasm, it must then traffic to the nucleus
in order for gene expression to occur. This step represents another significant barrier to gene
delivery. First, the cytoplasm contains nucleases that will degrade free DNA. Studies have
demonstrated that plasmid DNA is degraded in the cytoplasm of HeLa and COS cells with a
half-life of 50 to 90 minutes [60]. This poses a big problem for delivery of naked DNA and
DNA-lipid complexes that are believed to dissociate prior to nuclear entry. Additionally, the
cytoplasm itself poses a diffusional barrier as well. The cytoplasm is a viscous environment
crowded with molecules, which results in decreased mobility of macromolecules [61-63]. Thus,
if DNA is released from an endosome at a distant site from the nucleus, the DNA cannot simply
diffuse toward its desired location. This has been demonstrated in the case of liposome
transfections where some DNA is left free in the cytoplasm and never reaches the nucleus [64,
65]. Although it has been shown that lipoplex-containing endosomes themselves traffic toward
the nucleus and the interior of the cell, there is still quite a lot of distance for the free DNA
following endosomal release to move before it reaches the nucleus. We and others have shown
that DNA in the cytoplasm utilizes the microtubule network and the molecular motor, dynein
[66-68] for its trafficking to the nucleus. Since DNA does not directly bind to dynein, the
mechanism of this interaction was investigated and was found to involve a multiprotein
complex that bridges the DNA and dynein. Our laboratory has shown that transcription factors
are key proteins in this complex, and they are involved in the movement of DNA along
microtubules [69]. Furthermore, the velocity of plasmid DNA movement can be increased
through addition of specific transcription factor binding sites in the plasmid, such as CREB [69]
or by inducing acetylation of the microtubules themselves [70]. The acetylation status is largely
controlled by histone deacetylase 6 (HDAC6), and studies have shown that modulation of this
enzyme can increase the efficiency of gene transfer [70]. Thus, despite the fact that the
cytoplasm poses as a significant barrier to gene transfer, many techniques for overcoming this
problem are being revealed.
5. Nuclear import
DNA that has successfully navigated all of the barriers previously discussed finally comes into
contact with the nuclear envelope. However, depending upon cell type, DNA dose and
detection method, only 1 to 10% of transfected plasmid can be found within the nucleus [71,
72]. This suggests that an overwhelming proportion of DNA that enters the cytoplasm will
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never successfully enter the nucleus. It has been appreciated for over 30 years that the nuclear
envelope is a major barrier to DNA delivery [73]. Our laboratory has shown in microinjection
experiments using non-dividing cells that 30 to 100 times more plasmid must be injected into
the cytoplasm of a cell to equal levels of gene expression of plasmid injected directly into the
nucleus [74]. While it is true that DNA delivery to the nucleus is greater within dividing cells,
even breakdown of the nuclear envelope does not completely eliminate nuclear import as a
barrier to transfer [75]. Therefore, studies aimed at understanding how DNA is imported into
the nucleus as well as development of strategies to improve this process have been key to
enhancing the efficiency of non-viral gene delivery.
A number of studies have shown that the vast majority of transfected DNA enters the nucleus
during mitosis when the nuclear envelope has broken down [76, 77]. While plasmids can enter
the nucleus in the absence of cell division, the process is slow and highly inefficient, resulting
in very low levels of nuclear entry. However, our laboratory has shown that the delivery of
plasmid DNA into the nucleus can be greatly increased by the addition of specific DNA
sequences. We have demonstrated that plasmids containing only 72bp of the SV40 enhancer
are able to target the nucleus of non-dividing cells within a few hours [78]. This sequence,
termed a DNA nuclear targeting sequence (DTS), functions to enhance nuclear import in all
cell types tested. It is the presence of ubiquitously expressed transcription factor binding sites
within the SV40 DTS that mediate this effect. Since these transcription factors contain nuclear
localization signals (NLS) to allow their targeting to the nucleus, nuclear import of the DNA
is controlled by the interaction of these proteins with the NLS-receptors importin-α and
importin-β, that then transport cargo through the nuclear pore complex (NPC). Thus, when
NLS-containing transcription factors bind to the SV40 DTS on a plasmid, the plasmid utilizes
this system to enter the nucleus [79, 80]. We have shown that these DTS sequences act not only
in microinjected cells, but in transfected cells as well to increase DNA nuclear uptake and gene
expression as well as in tissues in living animals [81-83].
We have also identified several cell-specific DTSs, in which nuclear import of a plasmid is regu‐
lated by the presence of cell-specific transcription factor binding sites within the DTS. DTSs spe‐
cific for smooth muscle cells, osteoblasts, endothelial cells, alveolar epithelial type I cells and
alveolar epithelial type II cells have been identified and large studies are underway to screen
hundreds of DNA sequences for the potential to act as cell-specific DTSs [83-86]. In all of these
cases, the cell-specific DTS contains binding sites for cell specific transcription factors that are
expressed in unique cell types. Thus, if the plasmid is delivered to a cell that expresses those
transcription factors, it will be transported into the nucleus and gene expression will ensue; if,
however, the plasmid enters any other cell type that does not express the specific transcription
factor, the DNA will remain in the cytoplasm until cell division or until it is degraded by cyto‐
plasmic nucleases. Again, as for the SV40 DTS, these cell-specific DTSs work in cultured cells
and in animal tissues to increase gene expression in a cell-restricted manner [83, 86].
A number of other methods for enhancing nuclear import have been studied, all of which
center around exploiting the cells protein nuclear import machinery. These approaches include
complexing plasmid DNA with NLS peptides, nuclear proteins or small molecule ligands. The
success of NLS peptides has been variable, likely due to the fact that the NLS must be visible
Novel Gene Therapy Approaches80
to the importin proteins for nuclear import to occur [87]. However, in vivo studies using DNA
with conjugated NLS peptides have demonstrated increased gene expression in muscle as well
as increased immune response against the expressed antigen [88]. Also, more recently, analysis
of a bipartite NLS construct as a non-viral gene carrier has revealed the potential success of
this type of method over traditional monopartite peptides [89]. Due to the varied success of
NLS peptides at promotion of nuclear import, it is still unclear if this will be a promising
approach for gene therapy.
As an alternative to NLS peptides, some work has tested direct conjugation of importins to
plasmid DNA. The importin-β-binding domain of importin-α was covalently coupled to
plasmid DNA, but this also failed to enhance nuclear import [90]. In a separate study, a plasmid
DNA/importin-β conjugate was made via binding of biotinylated plasmid DNA and recombi‐
nant streptavidin-importin-β chimeric protein. While this did enhance nuclear import, gene
expression was very low due to the highly modified plasmid [91].
6. Conclusion
To maximize non-viral gene delivery, levels of expression must be improved. Unfortunately,
many extracellular and intracellular barriers (including the extracellular environment,
immune scavengers, the cell membrane, endosomal escape, the cytoskeletal network and the
nuclear membrane) preclude efficient gene transfer. In this review, we have focused on these
barriers and various means to overcome them. The goal of all gene therapy approaches is to
target enough DNA to the nuclei of cells to obtain sufficient expression for a therapeutic effect.
By characterizing and understanding these barriers, we can overcome our relative inability to
target substantial amounts of DNA to the nucleus and increase transfection efficiency and
ultimately gene therapy.
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